tirzepatide by eli lilly Lilly, Maker of Mounjaro and Zepbound, Wades Into Telehealth Eli Lilly (LLY) Gets Nod

AOD-9604 vs GLP-1 S GLP-1 S (semaglutide) works through an entirely different system than AOD-9604: it activates GLP-1 receptors to slow gastric emptying, increase satiety, and improve glycemic control, producing weight loss primarily by reducing food intake rather than by acting on fat cells directly

Many companies aside from Lilly and Novo Nordisk are also jumping on the train, testing their own GLP-1s in clinical trials, which could help with shortages in the future

Im glad to have been a part of the solution, he posted on X

understanding it helps you make consistent, informed choices across sessions

: Credits SUN PHARMA #pharmivonmedia #IndustryNews #SunPharma #DCGI #WeightLossTherapy #PharmaInnovation #IndianPharma #HealthcareNews #pharmacy #healthcare #pharmd #medical #industry To view or add a comment, sign in Indias pharma market continues to expand, reaching 2.4 lakh crore in 2025 and projecting ~8% growth in 2026

Cantidad neta: 1200 ml Ingredientes: agua purificada, L-Carnitina base, Taurina, acidulante: cido ctrico